Grantham Mayo Van Otterloo & Co. LLC Acquires 23,853 Shares of Humana Inc. (NYSE:HUM)

Grantham Mayo Van Otterloo & Co. LLC boosted its holdings in Humana Inc. (NYSE:HUM) by 144.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,365 shares of the insurance provider’s stock after acquiring an additional 23,853 shares during the period. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Humana were worth $10,241,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of Humana by 15.8% in the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after purchasing an additional 1,751,857 shares during the period. Norges Bank acquired a new position in Humana in the 4th quarter valued at about $416,202,000. Pzena Investment Management LLC raised its holdings in Humana by 44.0% in the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock valued at $915,736,000 after acquiring an additional 1,103,132 shares during the period. Boston Partners lifted its position in Humana by 435.8% during the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock worth $279,236,000 after acquiring an additional 893,637 shares during the last quarter. Finally, Artisan Partners Limited Partnership boosted its holdings in shares of Humana by 83.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 673,715 shares of the insurance provider’s stock worth $170,928,000 after acquiring an additional 306,433 shares during the period. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Price Performance

Shares of HUM stock opened at $253.37 on Monday. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The business has a fifty day simple moving average of $267.58 and a 200 day simple moving average of $271.55. The company has a market cap of $30.58 billion, a P/E ratio of 25.46, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a dividend yield of 1.40%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on HUM shares. Truist Financial lifted their price target on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. StockNews.com downgraded Humana from a “buy” rating to a “hold” rating in a report on Tuesday, March 18th. Barclays upped their price target on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research note on Thursday, February 13th. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 15th. Finally, Morgan Stanley decreased their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Eighteen analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $280.17.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.